ERBB2 and breast carcinoma: The prognostic effect and targetability of cytoplasmic Her2 is remained unknown in breast cancer because the related studies belong to the pre-trastuzumab years and the ASCO/CAP guideline does not endorse prescribing trastuzumab for the non-membraneous Her2 reactions.